Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2018, Article ID 7945845, 12 pages
Research Article

Elevated TERT Expression in TERT-Wildtype Adult Diffuse Gliomas: Histological Evaluation with a Novel TERT-Specific Antibody

1Department of Pathology, Tokyo Women’s Medical University, Tokyo 162-8666, Japan
2Department of Neuropathology, Tokyo Metropolitan Neurological Hospital, Tokyo 183-0042, Japan
3Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, Miyagi 980-8575, Japan
4Division of Cancer Stem Cell, National Cancer Center Research Institute, Tokyo 104-0045, Japan
5Division of Brain Tumor Translational Research, National Cancer Center Research Institute, Tokyo 104-0045, Japan
6Department of Pathology and Laboratory Medicine, Sendai Medical Center, Miyagi 983-0045, Japan
7Department of Neurosurgery, Tokyo Women’s Medical University, Tokyo 162-8666, Japan

Correspondence should be addressed to Takashi Komori;

Received 16 August 2017; Revised 10 December 2017; Accepted 17 January 2018; Published 5 March 2018

Academic Editor: Jens Schittenhelm

Copyright © 2018 Kenta Masui et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Telomerase reverse transcriptase (TERT) is important for the biology of diffuse gliomas. TERT promoter mutations are selectively observed among 1p/19q-codeleted oligodendrogliomas and isocitrate dehydrogenase gene- (IDH-) wildtype glioblastoma (GBM). However, TERT transcripts range widely in various cancers including gliomas, and TERT protein expression has been rarely investigated thus far. It would be thus critical to examine the expression level of TERT in tumors in addition to its mutational status, and sensitive and specific methods are urgently needed to examine TERT protein expression for the assessment of TERT biology in gliomas. Using our newly developed TERT-specific monoclonal antibody (TMab-6) applicable to human tissue, we found an unexpected increase in TERT expression in TERT-wildtype as well as TERT-mutated gliomas and in tumor vasculature. This is the first extensive analysis on the expression of TERT immunoreactivity in human glioma tissue, suggesting that TERT protein expression may be regulated by several mechanisms in addition to its promoter mutation.